Aktis Oncology, Inc. is a clinical-stage oncology company focused on developing targeted radiopharmaceuticals for the treatment of solid tumors. The company utilizes a proprietary miniprotein radioconjugate platform to deliver alpha-emitting radioisotopes, such as actinium-225, to specific tumor targets while minimizing systemic radiation exposure. Its lead product candidate, [225Ac]Ac-AKY-1189, targets Nectin-4 and is currently in a Phase 1b clinical trial for locally advanced or metastatic urothelial cancer and other Nectin-4 expressing solid tumors. The company is also developing a pipeline of other miniprotein radioconjugate programs targeting various clinically validated tumor antigens. Aktis Oncology is establishing internal manufacturing capabilities and a hybrid supply chain, including partnerships with isotope suppliers and contract manufacturers, to ensure reliable production of its radiopharmaceuticals.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage investors.aktisoncology.com
Sector Healthcare IR page investors.aktisoncology.com
Tags
radiopharmaceuticals, oncology, radioconjugates, alpha-emitters, targeted therapy, solid tumors, urothelial cancer, nuclear medicine, AKY-1189, [225Ac]Ac-AKY-1189
Press page —

Metrics

Valuation  
Market cap $ 1.05B
Market cap (USD) $ 1.05B
P/E -16.05
PEG —
P/BV 2.29
P/S 161.55
P/OCF -16.37
P/FCF -14.24
Dividend yield —
Turnover / mcap —
Returns  
ROE 43.6%
ROI —
ROIC —
Profit margin -980.9%
Growth  
Revenue growing —
Profits growing —
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 32
Quality score -37.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025
Revenue 6.497M
Net profit -63.731M
Free cash flow -73.711M

Filed figures

Figure Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — 11.5M
Cash and deposits (USD) 38.3M 37.8M
Right-of-use assets (USD) — 12.7M
Reported May 11, 2026 May 11, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

•Initiated the Company’s third Phase 1b clinical trial, BActinium-2, broadening the evaluation of AKY-2519 to lung cancer and other B7-H3 expressing tumors

•Started first backfill cohorts in the ongoing Phase 1b NECTINIUM-2 clinical trial of AKY-1189 and Phase 1b BActinium-1 clinical trial of AKY-2519

•On track to present preliminary data for AKY-1189 in first quarter of 2027 and AKY-2519 in 2027

BOSTON, November 12, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (“Aktis” or the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, today reported financial results for the third quarter ended September 30, 2026, and provided a business update, including progress with the Company’s two clinical-stage programs.

“Aktis is on a trajectory to redefine radiopharmaceuticals as a major pillar of cancer treatment by expanding the modality to more targets, broader indications, and larger patient populations.

10/01/2026

PDF Version

  • Phase 1b BActinium-2 clinical trial is evaluating AKY-2519 in patients with non-small cell lung cancer (NSCLC) and other B7-H3 expressing tumors

  • Enrollment is ongoing in the Phase 1b BActinium-1 clinical trial of AKY-2519 in metastatic castration-resistant prostate cancer (mCRPC); preliminary data expected in 2027

BOSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (“Aktis” or the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, today announced the initiation of the Phase 1b BActinium-2 trial of AKY-25191 in patients with NSCLC and other B7-H3 expressing solid tumor types. The BActinium-2 trial is part of Aktis’ clinical development strategy to develop AKY-2519 broadly in several B7-H3 expressing tumors. In May 2026, Aktis initiated the Phase 1b BActinium-1 trial of AKY-2519 in mCRPC patients, with preliminary data expected in 2027.

“AKY-2519 has the potential to be a differentiated therapeutic option for patients with B7-H3 expressing solid tumors, as demonstrated by the first-in-human clinical imaging and dosimetry data presented at ASCO earlier this year,” said Akos Czibere, MD, PhD, Chief Medical Officer at Aktis. “With both Phase 1b trials of AKY-2519 now underway, we are efficiently generating indication-relevant data in several cancers with large patient populations to evaluate where AKY-2519 can be most effective.”

The first-in-human clinical imaging and dosimetry data for AKY-2519 across mCRPC, NSCLC and other B7-H3 expressing tumor types presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in May 2026 demonstrated robust tumor uptake and retention of AKY-2519 with limited normal tissue exposure, suggesting the potential for a wide therapeutic window and differentiated profile compared to approved radiopharmaceuticals.

The Phase 1b, multicenter, open-label BActinium-2 trial will enroll patients with NSCLC and other B7-H3 expressing solid tumors. The study will explore three dose levels. Per protocol, Aktis has the ability to expand enrollment at selected dose levels to generate additional clinical data while dose escalation continues.

In addition to the AKY-2519 BActinium-1 and BActinium-2 trials, Aktis is also currently enrolling patients in an ongoing Phase 1b NECTINIUM-2 trial of its most advanced program, AKY-1189, a miniprotein radioconjugate targeting Nectin-4 expressing tumors, with preliminary data expected in the first quarter of 2027.

About Aktis’ miniprotein radioconjugate platform

Aktis has developed a proprietary, isotope-agnostic miniprotein radioconjugate platform to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors. Aktis’ therapeutic miniprotein radioconjugates are designed to maximize anticancer activity through high tumor penetration coupled with internalization and retention in cancer cells, while rapidly clearing from normal organs and tissues. The Aktis platform further enables clinicians to visualize and verify target engagement with imaging isotopes prior to exposure to therapeutic radioisotopes. Leveraging this platform, and its patient-first end-to-end clinical supply chain built for resiliency and scalability, Aktis is advancing a pipeline of next-generation targeted radiopharmaceuticals to address the unmet needs of patients across a broad spectrum of solid tumors.

About Aktis Oncology

Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. Aktis’ most advanced clinical-stage pipeline program, AKY-1189, is a miniprotein radioconjugate targeting Nectin-4, with multi-indication potential across multiple tumor types, including locally advanced or metastatic urothelial cancer, breast cancer, and other solid tumor cancers. Aktis’ second clinical-stage pipeline program, AKY-2519, is a miniprotein radioconjugate targeting B7-H3 expressing tumors, including prostate, lung, and other solid tumors. Aktis has a discovery collaboration with Eli Lilly and Company to leverage Aktis’ miniprotein platform to develop novel radioconjugates outside of its proprietary pipeline. For more information, please visit www.aktisoncology.com.

Forward-looking statements

This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the Company’s expectations about the timing and results of ongoing and planned clinical trials and regulatory filings, goals to develop and commercialize its product candidates, and other statements identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Forward looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond the Company’s control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to the commencement and completion of the Company’s ongoing and planned clinical trials, the Company’s limited operating history, its ability to generate positive clinical trial results for its product candidates and other risks inherent in clinical development, the timing and scope of regulatory approvals, changes in laws and regulations to which the Company is subject, competitive pressures, risks relating to business interruptions, and other risks set forth under the heading “Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended December 30, 2025 and in subsequent filings with the Securities and Exchange Commission. The Company’s actual results could differ materially from the results described in or implied by such forward looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, the Company undertakes no obligation to update or revise these forward-looking statements.

Media contact: Melone Communications, LLC Liz Melone 617-256-6622 [email protected]

Investor contact: Precision AQ Alex Lobo 212-698-8802 [email protected]

1AKY-2519 refers to the therapeutic radioconjugate [225Ac]Ac-AKY-2519.

Search Investors

09/09/2026

PDF Version

BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced that Matthew Roden, Ph.D., President and Chief Executive Officer of Aktis Oncology, will participate in the following investor conferences in September.

Morgan Stanley 24thAnnual Global Healthcare Conference Date & Time: Wednesday, September 16, 2026, at 8:30 a.m. ET Location: New York, NY

Oppenheimer 4thAnnual Targeted Radiopharmaceutical Therapies in Oncology Summit Date: Thursday, September 17, 2026 Location: New York, NY

A live webcast of the Morgan Stanley presentation may be accessed via the Investors section of the Aktis website at investors.aktisoncology.com. An archived replay of the event will be available on the website for approximately 90 days following the conference.

About Aktis’ Radioconjugate Platform

Aktis has developed a proprietary, isotope-agnostic miniprotein radioconjugate platform to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors. Aktis’ therapeutic miniprotein radioconjugates are designed to maximize anticancer activity through high tumor penetration coupled with internalization and retention in cancer cells, while rapidly clearing from normal organs and tissues. The Aktis platform further enables clinicians to visualize and verify target engagement with imaging isotopes prior to exposure to therapeutic radioisotopes. Leveraging this platform, and its patient-first end-to-end clinical supply chain built for resiliency and scalability, Aktis is advancing a pipeline of next-generation targeted radiopharmaceuticals to address the unmet needs of patients across a broad spectrum of solid tumors.

About Aktis Oncology

Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. Aktis’ most advanced clinical-stage pipeline program, AKY-1189, is a miniprotein radioconjugate targeting Nectin-4, with multi-indication potential across multiple tumor types, including locally advanced or metastatic urothelial cancer, breast cancer, and other solid tumor cancers. Aktis’ second clinical-stage pipeline program, AKY-2519, is a miniprotein radioconjugate targeting B7-H3 expressing tumors, including prostate, lung, and other solid tumors. Aktis has a discovery collaboration with Eli Lilly and Company to leverage Aktis’ miniprotein platform to develop novel radioconjugates outside of its proprietary pipeline. For more information, please visit www.aktisoncology.com.

Media contact: Melone Communications, LLC Liz Melone 617-256-6622 [email protected]

Investor contact: Precision AQ Alex Lobo 212-698-8802 [email protected]

Search Investors

Prompts

Aktis Oncology, Inc. (ticker AKTS), listed in United States.

ETFs Holding Aktis Oncology, Inc.

ETF Weight in ETF Shares Market value As of
YALL 1.30% 59,209 $ 956.817K Nov 17, 2026
TMED 0.21% 1,517 $ 48.893K Jun 30, 2026
RESM 0.03% 37 $ 1,192.51 Jun 30, 2026
AVUS 0.00% 11,132 $ 179.893K Nov 16, 2026
AVSU 0.00% 90 $ 1,454.40 Nov 16, 2026